Who to call at Esperion Therapeutics, Inc., and when
Fundz watches for the moments Esperion Therapeutics, Inc. starts buying, and tells you who to reach.
- An alert the day Esperion Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Esperion Therapeutics, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Esperion Therapeutics, Inc.. With Fundz connected, it knows.
Esperion Therapeutics, Inc.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
esperion.com2 executive changes at Esperion Therapeutics in the last 90 days. Clusters like this usually mean more senior seats open over the next few months.
See every company with multiple executive changes →AI Executive Summary
AI-powered analysis of 8-K filing content
Esperion Therapeutics appointed John B. Harlow, Jr. as Chief Commercial Officer, effective November 17, 2025, with a $535,000 base salary, a 45% target bonus, and equity grants of 380,000 options and 424,536 RSUs. The hire adds a commercial leader with prior CCO experience at Melinta Therapeutics and Baudax Bio.
Key Takeaways
Esperion filled its Chief Commercial Officer role with John B. Harlow, Jr., whose employment begins November 17, 2025.
Harlow's compensation package includes a $535,000 annual base salary, a target bonus of 45% of base salary, and a one-time $35,000 sign-on bonus.
2 more takeaways
Related Filings (7)
7 more filings from Esperion Therapeutics, Inc. in the last 90 days
Filing Overview
What This Means
Esperion Therapeutics, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.